Curasight to present at HC Andersen Capital
Copenhagen, Denmark, 22 February 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Annual Report 2022 and Year-End Report Q4 2022 at HC Andersen Capital, 27 February 2023.
The presentation will include an update on the momentum and business progress made by the company during 2022 and look ahead at the coming news flow expected in the first half of 2023. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer as well as Neuroendocrine and head & neck cancer.
The presentation will be webcasted live 14:00 - 14:30 (CET), Monday 27 February 2023.
An archive of the presentation can be found on the HC Andersesn Capital website as well as Curasight’s website, after the presentation is completed.
For more information – please click here
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.